For Business Use Only. Does Not Ship to Residential Addresses. For use inside an Analyzer, Sold Separately.
Thermo Kit Benz 100mL
Thermo Kit Benz 100mL
RECOMMEND SHIP UPS NEXT DAY AIR
Easily reorder reagents and American-made parts.
Enjoy the fair price promise.
Take pressure off your budget (and yourself)
Product Code: 0039
Manufacturer: Thermo Scientific
Shipping Weight: 2.00lbs (0.91kg)
Specifications
Control Sets: MGC Primary DAU Control Set
Description: DRI Benzodiazepine Drugs of Abuse Assays
Detectable Analytes: Oxazepam
DoA Calibrators: DRI Multi-Drug Calibrators
Quantity: 100mL
Storage Requirements: 2°to 8°C
Intended Use
The DRI® Benzodiazepine Assay is a homogeneous enzyme immunoassay intended for the qualitative and/or semi-quantitative determination of the presence of benzodiazepines and their metabolites in human urine at a cutoff concentration of 200 ng/mL. The assay is intended to be used in laboratories and provides a rapid analytical screening procedure to detect benzodiazepines in human urine. The assay is designed for use with a number of clinical chemistry analyzers. This assay is calibrated against Oxazepam. This product is intended to be used by trained professionals only.
The semi-quantitative mode is for the purpose of enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as Liquid Chromatography/tandem mass spectrometry (LC-MS/MS) or permitting laboratories to establish quality control procedures.
Summary and Explanation of the Test
Benzodiazepines are sedative-hypnotic drugs, which are subject to abuse. Benzodiazepines are structurally similar and include a wide variety of drugs such as alprazolam, chlordiazepoxide, diazepam, lorazepam, oxazepam and triazolam. They are absorbed and metabolized at different rates, resulting in various psychoactive effects. Therefore, the detection of benzodiazepines or their metabolites in urine can be used as an indicator of benzodiazepine abuse.
The DRI Benzodiazepine Assay is a homogeneous enzyme immunoassay with liquid readyto-use reagents. The assay uses a specific antibody which can detect most benzodiazepines and their metabolites in urine. The assay is based on the competition of an enzyme glucose6-phosphate dehydrogenase (G6PDH) labeled drug and the drug from the urine sample for a fixed amount of specific antibody binding sites. In the absence of free drug from the sample, the enzyme-labeled drug is bound by the specific antibody and the enzyme activity is inhibited. This phenomenon creates a relationship between drug concentration in urine and the enzyme activity. The enzyme G6PDH activity is determined spectrophotometrically at 340 nm by measuring its ability to convert nicotinamide adenine dinucleotide (NAD) to NADH.
